Nuveen’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Nuveen’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-337,165	Closed	-$8.13M	–	3375
2023 Q1	$8.13M	Sell	337,165 -74,141	-18%	-$930K	﹤0.01%	1617
2022 Q4	$4.35M	Buy	411,306 +29,409	+8%	+$237K	﹤0.01%	1995
2022 Q3	$1.72M	Sell	381,897 -739	-0.2%	-$3.37K	﹤0.01%	2475
2022 Q2	$1.53M	Sell	382,636 -62,906	-14%	-$298K	﹤0.01%	2579
2022 Q1	$3.29M	Sell	445,542 -418	-0.1%	-$2.5K	﹤0.01%	2279
2021 Q4	$2.51M	Buy	445,960 +8,335	+2%	+$52.9K	﹤0.01%	2461
2021 Q3	$2.92M	Buy	437,625 +209,786	+92%	+$1.35M	﹤0.01%	2498
2021 Q2	$1.92M	Sell	227,839 -117,027	-34%	-$944K	﹤0.01%	2731
2021 Q1	$3.62M	Buy	344,866 +3,137	+0.9%	+$44.1K	﹤0.01%	2328
2020 Q4	$5.79M	Sell	341,729 -32,570	-9%	-$488K	﹤0.01%	1992
2020 Q3	$4.8M	Buy	374,299 +207,787	+125%	+$2.62M	﹤0.01%	1937
2020 Q2	$2.35M	Buy	+166,512	New	+$2.1M	﹤0.01%	2272

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen's PRVB Position: Q2 2023 in Review

Nuveen sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 337,165 shares — an estimated $8.13M sold.

Nuveen first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $8.13M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Nuveen reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Nuveen sold 337,165 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $8.13M.
Nuveen first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
Nuveen's Provention Bio, Inc. Common Stock position peaked at $8.13M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.